Russell Rhoades, DO
Internal Medicine · Provo, UTNPI 1164436507
Payments from drug & device makers
Across 301 payments — averaging $15.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$869
- Lilly USA, LLC$488
- Novo Nordisk$378
- GSK$301
- Amgen$287
- AstraZeneca$284
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,673100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 50 | $869 |
| Lilly USA, LLC | 40 | $488 |
| Novo Nordisk | 34 | $378 |
| GSK | 21 | $301 |
| Amgen | 17 | $287 |
| AstraZeneca | 15 | $284 |
| Boehringer Ingelheim | 15 | $272 |
| Bayer | 15 | $247 |
| Pfizer | 20 | $245 |
| Astellas Pharma US Inc | 7 | $143 |
| Sanofi-aventis U.S. LLC | 9 | $134 |
| Phathom Pharmaceuticals, Inc. | 7 | $108 |
| Novartis | 4 | $75 |
| Averitas Pharma Inc. | 3 | $72 |
| Neurocrine Biosciences, Inc. | 4 | $69 |
| Nestle Healthcare Nutrition Inc. | 4 | $55 |
| Edwards Lifesciences | 2 | $55 |
| Johnson & Johnson | 3 | $52 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Baxter Healthcare | 1 | $41 |
| Radius Health, Inc. | 2 | $41 |
| Sanofi Pasteur Inc. | 2 | $38 |
| Actelion Pharmaceuticals US, Inc. | 3 | $38 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| Merck | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Daiichi Sankyo Inc. | 2 | $29 |
| Corcept Therapeutics | 1 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Boston Scientific | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $15 |
| Neurelis, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Grifols USA, LLC | 1 | $14 |
| Lucid Diagnostics Inc. | 1 | $13 |
How this compares
$4,673 in reported general payments places this provider in the 85th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 69 | $100,316 |
| EliquisApixaban | 102 | $96,274 |
| JardianceEmpagliflozin | 97 | $78,525 |
| TrulicityDulaglutide | 72 | $70,348 |
| OzempicSemaglutide | 63 | $68,691 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $42,682 |
| XareltoRivaroxaban | 24 | $35,632 |
| MyrbetriqMirabegron | 35 | $26,947 |
| RybelsusSemaglutide | 16 | $19,695 |
| GemtesaVibegron | 28 | $16,817 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $15,497 |
| KerendiaFinerenone | 14 | $12,151 |
| FarxigaDapagliflozin Propanediol | 11 | $10,498 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,401 |
| Levothyroxine Sodium | 435 | $5,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $488 | $170,664141 claims |
| PfizerEliquis | $245 | $96,274102 claims |
| Novo NordiskOzempic, Rybelsus | $378 | $88,38679 claims |
| Boehringer IngelheimJardiance | $272 | $78,52597 claims |
| Johnson & JohnsonXarelto | $52 | $35,63224 claims |
| Astellas Pharma US IncMyrbetriq | $143 | $26,94735 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $36 | $16,81728 claims |
| MerckJanumet | $34 | $15,49714 claims |
| BayerKerendia | $247 | $12,15114 claims |
| AstraZenecaFarxiga | $284 | $10,49811 claims |
| GSKTrelegy Ellipta | $301 | $8,40111 claims |
| NovartisEntresto | $75 | $3,62911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Provo
- Bryce SwensonProvo$9K
- Lawrence NobuharaProvo$9K
- Richard OlsenProvo$6K
- Ahad SabetSalt Lake City$34.5M
- Barbara RizzardiSandy$27.8M
- Willard DereSalt Lake City$4.7M
- Joseph WoolleySaint George$3.6M
- Justin MansfieldOgden$3.1M
- Michael KillpackSandy$2M
- Cuper Martinez SantibanezWest Valley City$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.